Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.

Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ.

Neurology. 2011 May 24;76(21):1811-6. doi: 10.1212/WNL.0b013e31821ccce4.

2.

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.

Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuki F, Takeda M, Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA, Chase TN; KW-6002 US-001 Study Group.

Neurology. 2003 Dec 9;61(11 Suppl 6):S97-100. Review.

PMID:
14663020
3.

A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.

Jones N, Bleickardt C, Mullins D, Parker E, Hodgson R.

Brain Res Bull. 2013 Sep;98:163-9. doi: 10.1016/j.brainresbull.2013.07.001. Epub 2013 Jul 6.

PMID:
23838432
4.

Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients.

Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K.

PLoS One. 2011 Feb 28;6(2):e17338. doi: 10.1371/journal.pone.0017338.

5.

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P.

J Clin Invest. 2014 Mar;124(3):1340-9. doi: 10.1172/JCI71640. Epub 2014 Feb 17.

6.

Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.

Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA.

Prog Neurobiol. 2007 Dec;83(5):293-309. Epub 2007 Jul 27. Review.

PMID:
17826884
7.
8.

Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.

Roussakis AA, Politis M, Towey D, Piccini P.

Neurology. 2016 Mar 22;86(12):1152-8. doi: 10.1212/WNL.0000000000002494. Epub 2016 Feb 26.

PMID:
26920358
9.

Adenosine receptors and dyskinesia in pathophysiology.

Tomiyama M.

Int Rev Neurobiol. 2014;119:117-26. doi: 10.1016/B978-0-12-801022-8.00005-2. Review.

PMID:
25175963
10.

Molecular imaging of levodopa-induced dyskinesias.

Niccolini F, Rocchi L, Politis M.

Cell Mol Life Sci. 2015 Jun;72(11):2107-17. doi: 10.1007/s00018-015-1854-x. Epub 2015 Feb 15. Review.

PMID:
25681866
11.

Non-dopaminergic treatments for motor control in Parkinson's disease.

Fox SH.

Drugs. 2013 Sep;73(13):1405-15. doi: 10.1007/s40265-013-0105-4. Review. Erratum in: Drugs. 2014 Jul;74(11):1305.

PMID:
23917951
12.

Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.

Mori A, Shindou T.

Neurology. 2003 Dec 9;61(11 Suppl 6):S44-8. Erratum in: Neurology. 2004 Jan 27;62(2):348.

PMID:
14663009
13.

Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.

Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.

Synapse. 2006 Sep 1;60(3):239-50.

PMID:
16739115
14.

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.

Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T.

J Neuropathol Exp Neurol. 2002 Feb;61(2):186-96.

PMID:
11853020
15.

Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.

Cerasa A, Salsone M, Morelli M, Pugliese P, Arabia G, Gioia CM, Novellino F, Quattrone A.

Parkinsonism Relat Disord. 2013 Oct;19(10):883-8. doi: 10.1016/j.parkreldis.2013.05.015. Epub 2013 Jun 14.

PMID:
23769805
16.

Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.

Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA.

Neurology. 2003 Dec 9;61(11 Suppl 6):S74-81.

PMID:
14663016
17.

Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.

Calon F, Dridi M, Hornykiewicz O, Bédard PJ, Rajput AH, Di Paolo T.

Brain. 2004 May;127(Pt 5):1075-84. Epub 2004 Mar 19.

PMID:
15033896
18.

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.

Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN.

Neurology. 2003 Aug 12;61(3):293-6.

PMID:
12913186
19.

Translating A2A antagonist KW6002 from animal models to parkinsonian patients.

Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD.

Neurology. 2003 Dec 9;61(11 Suppl 6):S107-11. Review.

PMID:
14663022
20.

Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.

Ongini E.

Neurology. 2003 Dec 9;61(11 Suppl 6):S72-3. No abstract available.

PMID:
14663015

Supplemental Content

Support Center